



## From the Editor

Brian C. Callaghan, MD, MS, and Kevin A. Kerber, MD, MS

Innovations in Care Delivery strives to highlight articles that feature advances in care delivery in our Editors' Blog, Editors' Top 5 Recommended Reading, and Latest Articles sections. Periodically, we also include interviews with leaders in the field of health services research.

### Editors' Blog

The Innovations in Care Delivery blog, over the last several months, has discussed articles about whether to use antiepileptic drugs after an unprovoked first seizure,<sup>1</sup> the role of monoclonal antibodies against CGRP receptors,<sup>2</sup> and the potential downsides of paraneoplastic testing.<sup>3</sup> Soon we will have a blog on the associations of continuous EEG on outcomes such as mortality, length of stay, and cost. Our goal is to highlight health services research articles published in *Neurology*<sup>®</sup> or *Neurology*<sup>®</sup>: *Clinical Practice* as well as to give informed opinions by experts in the field.

### Editors' Top 5 Recommended Reading and Latest Articles

Check out our collection of *Neurology* articles related to innovations in care delivery. Recent articles include the examination by Michelson et al.<sup>4</sup> of the evidence supporting nusinersen for spinal muscular atrophy. They found Class I evidence to support that treatment with nusinersen results in better milestone development, event-free survival, and motor function in patients treated early for spinal muscular atrophy. While this represents a fundamental breakthrough in the treatment of this rare condition, the cost is exorbitant and coverage is highly variable in the United States.

Another new addition is the article by Coelho et al.<sup>5</sup> that studied the effects of tafamidis and liver transplantation on mortality in patients with transthyretin-associated familial amyloid polyneuropathy (TTR-FAP). In their prospective cohort study, they found that both interventions improved mortality, but that life expectancy is still not normal even with treatment. As the new antisense oligonucleotides and siRNA medications become available for TTR-FAP, the role of these medications compared to previous interventions must be further studied. This condition now has several potential exciting treatments, but the precise role of each one is unclear and the costs are high.

### References

1. Bao EL, Chao LY, Ni P, et al. Antiepileptic drug treatment after an unprovoked first seizure: a decision analysis. *Neurology* 2018;91:e1429–e1439.
2. VanderPluym J, Dodick DW, Lipton RB, et al. Fremanezumab for preventive treatment of migraine: functional status on headache-free days. *Neurology* 2018;91:e1152–e1165.
3. Ebright MJ, Li SH, Reynolds E, et al. Unintended consequences of Mayo paraneoplastic evaluations. *Neurology* 2018;91:e2057–e2066.
4. Michelson D, Ciafaloni E, Ashwal S, et al. Evidence in focus: nusinersen use in spinal muscular atrophy: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. *Neurology* 2018;91:923–933.
5. Coelho T, Inês M, Conceição I, et al. Natural history and survival in stage 1 Val30Met transthyretin familial amyloid polyneuropathy. *Neurology* 2018;91:e1999–e2009.



## Blog

Read the Innovations in Care Delivery blog for timely posts by the editors and invited guests on *Neurology* articles. [NPub.org/icdblog](https://www.neurology.org/icdblog)

# Neurology<sup>®</sup>

## What's happening in Innovations in Care Delivery

*Neurology* 2019;92;273

DOI 10.1212/WNL.00000000000007018

### This information is current as of February 4, 2019

<b>Updated Information &amp; Services</b>	including high resolution figures, can be found at: <a href="http://n.neurology.org/content/92/6/273.full">http://n.neurology.org/content/92/6/273.full</a>
<b>References</b>	This article cites 5 articles, 5 of which you can access for free at: <a href="http://n.neurology.org/content/92/6/273.full#ref-list-1">http://n.neurology.org/content/92/6/273.full#ref-list-1</a>
<b>Permissions &amp; Licensing</b>	Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at: <a href="http://www.neurology.org/about/about_the_journal#permissions">http://www.neurology.org/about/about_the_journal#permissions</a>
<b>Reprints</b>	Information about ordering reprints can be found online: <a href="http://n.neurology.org/subscribers/advertise">http://n.neurology.org/subscribers/advertise</a>

*Neurology*® is the official journal of the American Academy of Neurology. Published continuously since 1951, it is now a weekly with 48 issues per year. Copyright © 2019 American Academy of Neurology. All rights reserved. Print ISSN: 0028-3878. Online ISSN: 1526-632X.

